Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Abstract

Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.).

Keywords

SitagliptinMedicineSemaglutidePlaceboHazard ratioSitagliptin PhosphateMyocardial infarctionInternal medicineGlycated hemoglobinAlogliptinGlycemicType 2 diabetesRelative riskConfidence intervalDiabetes mellitusDipeptidyl peptidase-4 inhibitorHeart failureEndocrinologyInsulinLiraglutide

Affiliated Institutions

Related Publications

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon , Richard E. Pratley , Samuel Dagogo‐Jack +12 more

Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Fu...

2020 New England Journal of Medicine 1396 citations

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White , Christopher P. Cannon , Simon Heller +10 more

Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor al...

2013 New England Journal of Medicine 2475 citations

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica , Deepak L. Bhatt , Eugene Braunwald +15 more

DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxaglip...

2013 New England Journal of Medicine 3396 citations

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

John B. Buse , Deborah J. Wexler , Απόστολος Τσάπας +5 more

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on...

2019 Diabetes Care 1135 citations

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Stephen D. Wiviott , Itamar Raz , Marc P. Bonaca +17 more

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MAC...

2018 New England Journal of Medicine 5890 citations

Publication Info

Year: 2015
Type: article
Volume: 373
Issue: 3
Pages: 232-242
Citations: 2519
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2519

OpenAlex

Cite This

APA Style

                            
                                
                                    Jennifer B. Green, 
                                
                                    M. Angelyn Bethel, 
                                
                                    Paul W. Armstrong
                                
                                et al.
                            
                            (2015). 
                            Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 373
                            (3)
                            , 232-242.
                            https://doi.org/10.1056/nejmoa1501352
                        

Identifiers

DOI: 10.1056/nejmoa1501352